• Valentina Carozzi, Alessia Chiorazzi, Annalisa Canta, Norberto Oggioni, Alessandra Gilardini, Virginia Rodriguez-Menendez, Federica Avezza, Luca Crippa, Cecilia Ceresa, Gabriella Nicolini, Mario Bossi, and Guido Cavaletti.
• Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Via Cadore 48, 20052 Monza (MI), Italy.
• Eur. J. Cancer. 2009 Mar 1; 45 (4): 656-65.

AbstractWe have characterised for the first time the general and neurological side effects experienced when using a series of chronic non-lethal cisplatin + paclitaxel schedules in Wistar rats, selected according to our previous experience and the animals' maximum tolerated dose. At the pathological level, the use of combination schedules was definitely more toxic at the kidney and sternal bone marrow level than the single-agent schedules. At the neurophysiological examination based on the assessment of the nerve conduction velocity measurement in the tail nerve, we identified only one combination schedule that was more neurotoxic than the similar schedules based on single-agent administration. This observation was confirmed by the neuropathological examination performed on the sciatic nerve, dorsal root ganglia, ventral and dorsal roots. Our study supports the hypothesis that the general and, to a lesser extent, neurological effects of a combination of cisplatin and paclitaxel are different from those of the administration of both drugs as single agents. We believe that these models may be useful for testing neuroprotective strategies.

28 keywords...

hide…